Company intelligence / Profile preview
Fulgent Pharma
El Monte, California, United Statesfulgentpharma.com ↗
- Ownership
- Public · FLGT
- Development stage
- Other
01
Overview
Fulgent Pharma’s lead asset, FID-007—a nanoencapsulated formulation of paclitaxel—has advanced into Phase 2 clinical trials for advanced head and neck squamous cell carcinoma. The company is also developing additional candidates targeting a range of solid tumors using its proprietary nano-drug delivery platform. Some earlier-stage or discontinued programs include those for pancreatic cancer and other neoplasms.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeAntibody-drug conjugateNanoparticle
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
University of Southern CaliforniaMoffitt Cancer CenterANP Technologies
04
Financials
- Market cap
- $513.4M
- Total revenue
- $322.7M
- Enterprise value
- $-138.4M
Beyond the preview
Go deeper on Fulgent Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fulgent Pharma.